Cargando…
Real-World Data Collection from Expanded Access Case Studies for the Treatment of Nontuberculous Mycobacterial Infection with Clofazimine
BACKGROUND: Due to its indolent nature, nontuberculous mycobacteria (NTM) are increasing in global prevalence as a cause of pulmonary infections and are difficult to treat with traditional antibiotics. Here, we study the repurposing of clofazimine (CFZ) to treat NTM through expanded access in a sing...
Autores principales: | Gravelin, Misty, Nguyen, Theophilus, Davies, Madeleine, Richards, Blair, Sexton, Jonathan Z., Gregg, Kevin, Weatherwax, Kevin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635239/ https://www.ncbi.nlm.nih.gov/pubmed/37961189 http://dx.doi.org/10.1101/2023.10.30.23297757 |
Ejemplares similares
-
2276 Development of the expanded access oversight committee at Michigan Medicine
por: Weatherwax, Kevin, et al.
Publicado: (2018) -
400 Exploring the Diversity of Expanded Access Patients at Michigan Medicine
por: Gravelin, Misty, et al.
Publicado: (2023) -
Adapting an Expanded Access program to enable investigational treatments for COVID-19
por: Samuels, Elias, et al.
Publicado: (2022) -
Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche
por: McGuffin, Sarah A, et al.
Publicado: (2017) -
Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights
por: Holbein, M. E. Blair, et al.
Publicado: (2018)